GLAM - ETF AI Analysis
Top Page
Corgi Beauty, Skincare & Aesthetics ETF (GLAM)
Rating:62Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year, showing positive momentum for investors.
Leading Holdings With Strong Gains
Several of the largest positions, such as AbbVie, Colgate-Palmolive, and other beauty and healthcare names, have shown strong performance, helping drive the fund’s returns.
Focused Yet Diversified Sector Mix
The fund spreads its assets across health care, consumer defensive, and consumer cyclical companies tied to beauty and skincare, reducing the impact if one of these areas hits a rough patch.
Negative Factors
High U.S. Concentration
With almost all assets in U.S. companies, the ETF offers little geographic diversification and is heavily tied to the U.S. economy.
Meaningful Weight In Lagging Stocks
Some notable holdings like Estée Lauder, Ulta Beauty, and Hims & Hers Health have shown weak recent performance, which can drag on overall returns if the weakness continues.
Moderate Expense Ratio For A Small Fund
The fund’s fee is not especially low and, combined with its relatively small asset base, may be a consideration for cost-conscious investors.
GLAM vs. SPDR S&P 500 ETF (SPY)
AUM1.41M
RegionGlobal
Expense Ratio0.35%
Beta0.55
IssuerCorgi
Inception DateMay 06, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume183
30 Day Avg. Volume1,602
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
33.04Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GLAM Summary
GLAM is the Corgi Beauty, Skincare & Aesthetics ETF, an actively managed fund focused on the global beauty and personal care theme rather than a traditional index. It invests in companies that make skincare, makeup, hair products, fragrances, packaging, and medical-aesthetic treatments. Well-known holdings include Colgate-Palmolive and Estée Lauder. Someone might invest in GLAM to get growth-oriented, diversified exposure to the beauty and personal care industry, which can benefit from long-term trends like aging populations and rising incomes. A key risk is that it’s concentrated in one sector, so its price can swing more than a broad market fund.
How much will it cost me?This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s higher than the cost of a typical broad, passively managed index ETF because this is an actively managed, specialized fund focused on the beauty and personal care sector.
What would affect this ETF?This ETF could benefit if global consumer spending on beauty and personal care keeps growing, especially as aging populations, higher incomes, and online shopping support demand for brands like Colgate-Palmolive, Estée Lauder, and Ulta Beauty, while medical-aesthetics names such as AbbVie and Align gain from increased interest in cosmetic treatments. On the downside, it is heavily focused on health care and consumer staples, so tighter health regulations, changes in drug or cosmetic approvals, weaker consumer confidence, or higher interest rates that hurt growth stocks and global markets could weigh on its performance.
GLAM Top 10 Holdings
GLAM leans heavily on health care and consumer staples, with AbbVie acting as the main engine thanks to its rising share price and hefty weight in the portfolio. On the beauty side, International Flavors & Fragrances and e.l.f. Beauty have been climbing, giving the fund an extra lift, while Evolus adds a more speculative, fast-moving flavor. Offsetting that strength, Colgate-Palmolive and Kenvue have been lagging, and Hims & Hers has stumbled lately. Overall, this is a globally focused bet on the beauty and personal care ecosystem, not just U.S. megacaps.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AbbVie | 14.92% | $209.44K | $467.12B | 19.32% | 66 Neutral | |
| Colgate-Palmolive | 7.23% | $101.53K | $68.60B | 7.61% | 63 Neutral | |
| The Estée Lauder Companies | 5.64% | $79.16K | $34.18B | 7.22% | 56 Neutral | |
| International Flavors & Fragrances | 5.57% | $78.12K | $21.86B | 40.62% | 61 Neutral | |
| Ulta Beauty | 5.24% | $73.54K | $23.31B | -0.83% | 78 Outperform | |
| e.l.f. Beauty | 5.16% | $72.41K | $5.87B | -22.41% | 68 Neutral | |
| Kenvue, Inc. | 4.64% | $65.16K | $34.19B | 9.42% | 73 Outperform | |
| Hims & Hers Health | 4.40% | $61.81K | $6.86B | -51.32% | 68 Neutral | |
| AptarGroup | 4.13% | $57.99K | $7.88B | -5.91% | 60 Neutral | |
| Evolus | 3.68% | $51.69K | $526.42M | 29.64% | 50 Neutral |
GLAM Technical Analysis
Negative
―
Price Trends
28.39
Negative
Market Momentum
-0.08
Positive
48.44
Neutral
35.74
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GLAM, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 28.31, equal to the 50-day MA of 28.39, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 48.44 is Neutral, neither overbought nor oversold. The STOCH value of 35.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GLAM.
GLAM Peer Comparison
Comparison Results
Performance Comparison
GLAM
Corgi Beauty, Skincare & Aesthetics ETF
28.18
2.64
10.34%
FFND
Future Fund Active ETF
―
―
―
FITZ
Fitz-Gerald Must Have Portfolio ETF
―
―
―
IQM
Franklin Intelligent Machines ETF
―
―
―
HECO
SPDR Galaxy Hedged Digital Asset Ecosystem ETF
―
―
―
BREW
Corgi Coffee & Energy Drinks ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents